Loading
Soligenix, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by SCHABER CHRISTOPHER J, was filed 03 Oct 2025.
Soligenix, Inc.: what insiders have been doing
This page follows insider dealings at Soligenix, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Nothing new has been filed by managers of Soligenix, Inc. in twelve months, the latest record being from 3 October 2025.
Looking back to 2016, when coverage begins, insiders filed 20 purchases and 11 sales.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
33
Thresholds
n/a
Buy Volume
€334,118
20 ops. · all time
Sell Volume
€984,576
11 ops. · all time
Who traded when
BuySaleChristopher J. Schaber1 buy
Since the insiders bought
- -73.7%Entry US$1.37 · Close at T+365 US$0.36
- -89.4%Entry US$117.60 · Close at T+365 US$12.48
- -12.5%Entry US$172.80 · Close at T+365 US$151.20
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 26,234 of 26,250 companies
1.8
score / 100
Value1
Quality3
FCF yld-134%
Earn yld-144%
EV/EBITDA·
ROE-242%
Gross mgn5.0%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.35
Analyst consensus
2 analysts1.00/5
US$1.25Target US$1.38(+289%)US$1.50
Income statement
RevenueUS$1.7M
Gross profitUS$83.8k5% margin
EBITDA-US$11.8M-712% margin
Net income-US$11.1M0.0% margin
Valuation
PER (forward)-1.4x
P/Book1.2x
Beta2.00
Balance sheet & cash
Market capUS$7.7M
Total debtUS$358.1k
Free Cash Flow-US$10.3M
Debt / Equity5%
Profitability & ownership
ROE-241.7%
ROA-84.9%
% insiders4.6%
% institutions6.7%
Last declaration on 3 October 2025
Declarations33 total
15,132 shares@ US$1.321746.7% of flowCommon StockSEC:0001068029-25-000003:0
Canonical exit: 31 Dec 2025 (T+90)
8,000 shares@ US$0.50100.0% of flowCOMMON STOCKSEC:0001415889-22-005252:0
Canonical exit: 16 Aug 2022 (T+90)
20,000 shares@ US$0.443323.2% of flowCommon StockSEC:0001415889-22-005251:0
Canonical exit: 16 Aug 2022 (T+90)
7,000 shares@ US$0.739912.5% of flowCOMMON STOCKSEC:0001415889-21-006124:0
Canonical exit: 17 Mar 2022 (T+90)
1,000 shares@ US$0.709.0% of flowCOMMON STOCKSEC:0001104659-21-149979:0
Canonical exit: 15 Mar 2022 (T+90)
10,000 shares@ US$0.711991.0% of flowCOMMON STOCKSEC:0001104659-21-149786:0
Canonical exit: 14 Mar 2022 (T+90)
10,000 shares@ US$0.726917.6% of flowCOMMON STOCKSEC:0001104659-21-149557:0
Canonical exit: 14 Mar 2022 (T+90)
3,000 shares@ US$0.900214.0% of flowCommon StockSEC:0001213900-21-027682:1
3,000 shares@ US$0.888100.0% of flowCommon StockSEC:0001213900-21-027682:0
Canonical exit: 12 Aug 2021 (T+90)
10,770 shares@ US$0.9314.6% of flowCommon StockSEC:0001213900-19-024070:0
Canonical exit: 17 Feb 2020 (T+90)
2,000 shares@ US$0.92512.2% of flowCommon StockSEC:0001213900-19-024072:0
Canonical exit: 17 Feb 2020 (T+90)
4,000 shares@ US$0.93524.7% of flowCommon StockSEC:0001213900-19-018664:0
Canonical exit: 18 Dec 2019 (T+90)
14,940 shares@ US$0.9284100.0% of flowCommon StockSEC:0001213900-19-018706:0
Canonical exit: 22 Dec 2019 (T+90)
78,338 shares@ US$0.7122.2% of flowCommon StockSEC:0001213900-19-012450:0
5,000 shares@ US$0.71545.1% of flowCommon StockSEC:0001213900-19-006871:0
Canonical exit: 21 Jul 2019 (T+90)
10,000 shares@ US$0.727447.1% of flowCommon StockSEC:0001213900-19-006872:0
Canonical exit: 21 Jul 2019 (T+90)
8,700 shares@ US$1.1714.3% of flowCommon StockSEC:0001213900-18-014092:0
Canonical exit: 16 Jan 2019 (T+90)
170,000 shares@ US$1.1677.8% of flowCommon StockSEC:0001213900-18-014061:0
Canonical exit: 15 Jan 2019 (T+90)
3,530 shares@ US$1.427.0% of flowCommon StockSEC:0001213900-18-011576:0
Canonical exit: 20 Nov 2018 (T+90)
271,140 shares@ US$2.1292.4% of flowCommon StockSEC:0001213900-17-012851:0
5,954 shares@ US$2.122.0% of flowCommon StockSEC:0001213900-17-012851:2
16,416 shares@ US$2.125.6% of flowCommon StockSEC:0001213900-17-012851:4
49,875 shares@ US$4.0128.5% of flowCommon StockSEC:0001140361-17-018903:1
11,739 shares@ US$2.975.0% of flowCommon StockSEC:0001140361-17-018903:2
2,278 shares@ US$2.971.0% of flowCommon StockSEC:0001140361-17-018903:5
25 of 33 declarations
About Soligenix, Inc.
Soligenix, Inc. is a specialty biopharmaceutical company listed on the Nasdaq Capital Market under the ticker SNGX in the United States. For French-speaking investors, it fits the profile of a development-stage biotech: valuation is primarily driven by clinical milestones, regulatory progress, and financing capacity rather than recurring product revenue. The company has operated under several legacy names before adopting Soligenix, Inc. in 2009, reflecting a long corporate history in life sciences. Its principal executive office is in Princeton, New Jersey, United States.
Soligenix describes itself as a late-stage biopharmaceutical company focused on rare diseases and other areas of unmet medical need. The business is organized into two segments. Specialized BioTherapeutics is the core value-creation engine and houses the company’s lead therapeutic programs. Its flagship asset is HyBryte™, a synthetic hypericin-based photodynamic therapy being developed for cutaneous T-cell lymphoma (CTCL), a rare form of skin lymphoma. The company is also developing SGX302 for psoriasis, alongside its Innate Defense Regulator platform, including SGX942 for oral mucositis in head and neck cancer and SGX945 for aphthous ulcers associated with Behçet’s disease. The second segment, Public Health Solutions, includes biodefense and public-health programs such as RiVax®, a ricin toxin vaccine candidate, as well as work targeting viral threats including Ebola, Marburg, and certain coronavirus programs.
Read moreShow less
From a competitive standpoint, Soligenix occupies a highly specialized niche where differentiation depends on science, intellectual property, and clinical validation. Its investment case is built around orphan and underserved indications, where market size may be limited but pricing power and regulatory incentives can be attractive if clinical proof is achieved. HyBryte™ is the main program to watch. The company has advanced the asset through phase 3 development, and its recent disclosures indicate a confirmatory Phase 3 FLASH2 study is underway. That makes the name particularly sensitive to trial design, enrollment pace, interim readouts, and the ability to convert clinical progress into a viable regulatory path.
Recent events reinforce the company’s development-stage profile. Soligenix began patient enrollment in FLASH2 in December 2024, and SEC filings indicate an interim analysis is expected in the second quarter of 2026, with top-line results anticipated in the second half of 2026. The company also completed financing transactions in 2025, underscoring that access to capital remains central to execution. For investors following U.S.-listed biotech names on the Nasdaq, Soligenix is best viewed as a clinical catalyst story with multiple pipeline shots on goal, but with meaningful dilution and execution risk until a clear regulatory and commercial path is established.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
